肺纤维化
特发性肺纤维化
博莱霉素
肺
纤维化
肌成纤维细胞
医学
药理学
体内
癌症研究
生物
病理
内科学
化疗
生物技术
作者
Shengchuan Bao,Ting Chen,Xinguang Chen,Jiaxiang Zhang,Guangjian Zhang,Hui Ye,Jingtao Li,Yan Su
出处
期刊:Phytomedicine
[Elsevier]
日期:2023-12-01
卷期号:121: 155078-155078
被引量:2
标识
DOI:10.1016/j.phymed.2023.155078
摘要
Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease with limited therapeutic strategies. Therefore, there is an urgent need to search for safe and effective drugs to treat this condition. Ophiopogonin D (OP-D), a steroidal saponin compound extracted from ophiopogon, possesses various pharmacological properties, including anti-inflammatory, antioxidant, and antitumor effects. However, the potential pharmacological effect of OP-D on pulmonary fibrosis remains unknown.The aim of this study was to investigate whether OP-D can improve pulmonary fibrosis and to explore its mechanism of action.The effect of OP-D on pulmonary fibrosis was investigated in vitro and in vivo using a mouse model of IPF induced by bleomycin and an in vitro model of human embryonic lung fibroblasts induced by transforming growth factor-β1 (TGF-β1). The mechanism of action of OP-D was determined using multi-omics techniques and bioinformatics.OP-D attenuated epithelial-mesenchymal transition and excessive deposition of extracellular matrix in the lungs, promoted the apoptosis of lung fibroblasts, and blocked the differentiation of lung fibroblasts into myofibroblasts. The multi-omics techniques and bioinformatics analysis revealed that OP-D blocked the AKT/GSK3β pathway, and the combination of a PI3K/AKT inhibitor and OP-D was effective in alleviating pulmonary fibrosis.This study demonstrated for the first time that OP-D can reduce lung inflammation and fibrosis. OP-D is thus a potential new drug for the prevention and treatment of pulmonary fibrosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI